Insight Molecular Diagnostics Inc IMDX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
iMDx Welcomes New Diagnostics Sales Leader to Prepare for Planned GraftAssureDx Launch
-
iMDx to Participate in Virtual U.S. Bancorp I BTIG Kidney Health Forum with KOL Discussion and Investor Meetings
-
iMDx to Participate in Lake Street 10th Annual Best Ideas Growth “BIG10” Conference
-
Insight Molecular Diagnostics to Host Virtual KOL Event on August 17, 2026: Moving Toward In-House Heart Transplanted Organ Rejection Testing
-
IMDX Reports Second Quarter 2026 Results and Timely Progress on FDA Review of GraftAssureDx
-
iMDx to Release Second Quarter Results on August 10, 2026 and Attend Needham Virtual MedTech & Diagnostics 1x1 Conference
Trading Information
- Previous Close Price
- $3.00
- Day Range
- $2.93–3.25
- 52-Week Range
- $2.42–8.51
- Bid/Ask
- $2.45 / $3.77
- Shares Outstanding
- 32.72M
- Market Cap
- $103.41M
- Volume/Avg
- 306,875 / 243,937
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 64.07
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Insight Molecular Diagnostics Inc is a pioneering diagnostics technology company whose mission is to democratize access to novel molecular diagnostic testing to improve patient outcomes. The Company's flagship technology quantifies a molecular biomarker known as donor-derived cell-free DNA (dd-cfDNA). It is also in the process of rebranding its RUO test kit, GraftAssure, as GraftAssureIQ, and rebranding its future in-vitro diagnostic (IVD) test kit as GraftAssureDx. The company geographically operates in the United States, the United Kingdom, Europe, and the Asia-Pacific regions, with maximum revenue generated from the USA.
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- Stock Style Box
- Small Value
- Total Number of Employees
- 58
- Website
- https://www.imdxinc.com
Valuation
|
Metric
|
IMDX
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | — |
Price/Sales | 64.07 |
Price/Cash Flow | — |
Price/Earnings
IMDX
Financial Strength
|
Metric
|
IMDX
|
|---|---|
Quick Ratio | 1.74 |
Current Ratio | 2.00 |
Interest Coverage | −502.66 |
Quick Ratio
IMDX
Profitability
|
Metric
|
IMDX
|
|---|---|
Return on Assets (Normalized) | −88.02% |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | — |
Return on Assets
IMDX
Diagnostics & Research Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Thermo Fisher Scientific Inc
TMO
| LOCK|$F#?dVRN | LOCK|cx@ | $256B | |||
| Danaher Corp
DHR
| LOCK|q#m#?<$s | LOCK|D&W | $163B | |||
| Agilent Technologies Inc
A
| LOCK|G#<^C<d< | LOCK|&? | $50B | |||
| Waters Corp
WAT
| LOCK|&dlF?W> | LOCK|V# | $46B | |||
| IQVIA Holdings Inc
IQV
| LOCK|XTSXCM | LOCK|>C^d | $45B | |||
| IDEXX Laboratories Inc
IDXX
| LOCK|mw^P!$K$ | LOCK|f@M | $44B | |||
| Illumina Inc
ILMN
| LOCK|XP%#k@& | LOCK|^RB?$ | $42B | |||
| Mettler-Toledo International Inc
MTD
| LOCK|<N%@%bT | LOCK|#yJ> | $34B | |||
| Labcorp Holdings Inc
LH
| LOCK|bVqd@^g | LOCK|pm<gL | $27B | |||
| Quest Diagnostics Inc
DGX
| LOCK|@%Kn?n | LOCK|mFVB! | $27B |
United States